Kristopher A. Lofgren, Ph.D.
Affiliations: | 2005-2010 | Microbiology, Immunology, and Cancer Biology | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Cell Biology, OncologyGoogle:
"Kristopher Lofgren"Parents
Sign in to add mentor| Carol A. Lange | grad student | 2010 | UMN | |
| (Modeling Brk/PTK6 Expression in the Mammary Epithelium.) | ||||
| Donald E. Ingber | post-doc | 2010-2013 | Boston Children's Hospital/Harvard Medical School (Neurotree) | |
| Paraic A. Kenny | post-doc | 2013-2015 | Albert Einstein College of Medicine of Yeshiva University | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lofgren KA, Kenny PA. (2023) Grb7 knockout mice develop normally but litters born to knockout females fail to thrive. Developmental Dynamics : An Official Publication of the American Association of Anatomists |
| Lofgren KA, Reker NC, Sreekumar S, et al. (2022) Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate. Antibody Therapeutics. 5: 226-231 |
| Parsons BM, Meier DR, Gurda GT, et al. (2022) Exceptional Response to Crizotinib in an MET-Amplified Triple-Negative Breast Tumor. Jco Precision Oncology. 1: 1-6 |
| Lofgren KA, Sreekumar S, Jenkins EC, et al. (2021) Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer. Antibody Therapeutics. 4: 252-261 |
| Parsons BM, Meier DR, Richmond CS, et al. (2020) Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Clinical Breast Cancer |
| Meier DR, Girtman MA, Lofgren KA, et al. (2019) Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice. Breast Cancer Research and Treatment |
| Lofgren K, Emmanuel N, Meier D, et al. (2019) SAT-331 Elucidating the Role of Breast Cancer Specific GATA3 Mutation in Estrogen Receptor Positive Breast Cancer Journal of the Endocrine Society. 3 |
| Parsons BM, Meier DR, Sreekumar S, et al. (2019) Abstract 1317: Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations Cancer Research. 79: 1317-1317 |
| Emmanuel N, Lofgren KA, Peterson EA, et al. (2018) Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells. Anticancer Research. 38: 4435-4441 |
| Meier DR, Lofgren KA, Gurda GT, et al. (2018) Adaptation of an amplicon-based human cancer next-generation sequencing panel assay for murine tumors. Analytical Biochemistry |